GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Is GlaxoSmithKline (GSK) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick GlaxoSmithKline (GSK) Stock?

GlaxoSmithKline GSK, +1.21% GSK, -1.61% was downgraded to underweight from equal weight by Barclays, which said 2020 looks to be a much tougher investment year for the pharma giant without much growth.

GlaxoSmithKline cut to underweight at Barclays

Pfizer

Pfizer Inc. is planning an initial public offering of its consumer-health joint venture with GlaxoSmithKline Plc in three to four years.

Pfizer Eyes IPO Of Glaxo Consumer Venture In 3 To 4 Years

GlaxoSmithKline CEO Emma Walmsley told "Mad Money" host Jim Cramer the British drugmaker has received "positive data" for cancer and HIV drugs.

GlaxoSmithKline CEO expects to get 'at least' six drug approvals from the FDA in 2020

Glaxo (GSK) submits an MAA in Europe for its investigational candidate fostemsavir, which is being developed for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Glaxo Files Marketing Application for Fostemsavir in Europe

CenterPoint Energy

These stocks aren't overvalued the way much of the market is today.

3 Dividend Stocks Yielding More Than 4% That Are Safe Buys in 2020

Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.

Glaxo (GSK) Shares Continue to Witness Upside: Here's Why

Eli Lilly

GSK's stock performed better in 2019, but will it remain that way in 2020?

Better Buy: Eli Lilly vs. GlaxoSmithKline

Biogen

Bristol-Myers

Gilead Sciences

Sanofi

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year's Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors.

More drugmakers hike U.S. prices as new year begins

Drugmakers including Pfizer Inc , GlaxoSmithKline PLC  and Sanofi SA  are planning to hike prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

Amgen

Dova Pharma

Dova combined with Sobi spells threat for a part of the business for Amgen and GlaxoSmithKline.

Sobi + Dova: A Threat For Amgen And GlaxoSmithKline

Medtronic

Merck

By Robert Ross 2019 was a good year for stocks. US stocks have rocketed 28% this year.

3 Ways to Play the Healthcare Surge

GlaxoSmithKline (GSK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry

GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.

GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA

Bank of Nova Scotia

Mobile TeleSystems

One overseas income stock has what looks to be a sustainable payout of nearly 10%

3 High-Yield International Dividend Stocks to Consider Buying Now

Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.

Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why GlaxoSmithKline (GSK) is a Great Choice

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is GlaxoSmithKline (GSK) a Great Value Stock Right Now?

Roche Holding AG

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

AbbVie

AbbVie and GlaxoSmithKline are both poised for a big 2020. Still, one stock is clearly the better buy right now.

Better Buy: AbbVie vs. GlaxoSmithKline

SAN DIEGO, Nov.  22, 2019  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.

Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management

Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

Novo Nordisk

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

4 Big Drugmakers to Bet on After a Great Earnings Season

GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales.

News for GlaxoSmithKline Stock (GSK)